Protective Effects of Insulin and Incretins in AD/PD

Protective Effects of Insulin and Incretins in AD/PD

Tuesday, March 9, 2021
14:00 – 19:00
Pre-registration is required. To register, please click here.

Session Chair: Christian Hölscher

Time

Name

Country

Lecture Title

13:50 -14:00 Christian Hölscher China Welcome and Introduction
14:00-14:20 Suzanne Craft USA Intranasal insulin as a therapy for Alzheimer’s disease
14:20-14:40 Tom Foltynie UK Clinical trial of Bydureon (exenatide) in PD patients
14:40-15:00 Paul Edison UK Clinical trial of liraglutide in AD patients
15:00-15:20 Michele Tagliati USA Clinical trial of liraglutide in PD patients
15:20-15:40 Wassilios Meissner France Impaired brain insulin signalling in synucleinopathies: a translational study
15:40-16:00 Dimitrios Kapogiannis USA Insulin signaling biomarkers in blood exosomes of AD and PD patients
16:00-16:20 Coffee Break
16:20-16:40 Konrad Talbot USA Direct demonstration of brain insulin resistance in Alzheimer’s and Parkinson’s disease dementia and its alleviation with incretin receptor agonists
16:40-17:00 William Banks USA Permeability of the blood-brain barrier to insulin and incretins
17:00-17:20 Fernanda G. De Felice Brazil Defective hormonal signalling in Alzheimer’s disease
17:20-17:40 Nigel Greig USA GLP-1R agonists in traumatic brain injury
17:40-18:00 Ana Isabel Duarte Portugal The neuroprotective effects of insulin/IGF-1/GLP-1 signalling recovery in type 2 diabetes and neurodegenerative diseases
18:00-18:20 Christian Hölscher China Novel dual GLP-1/GIP receptor agonists and are superior to single receptor agonists in animal models of Alzheimer and Parkinson’s disease
18:20-18:55 All Round Table Dicussion
18:55 – 19:00 Christian Hölscher Closing Remarks